Compare BioNano Genomics Inc (BNGO) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Match Group Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Match Group Inc trades at $39.9 (market cap $8.94B). The key difference: Match Group Inc is far larger — about 677.3× BioNano Genomics Inc's market cap, and Match Group Inc pays a 2.09% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | MTCH | |
|---|---|---|
Market Cap | $13.20M | $8.94B |
Sector | Health | Media |
52-Week High | $4.92 | $39.32 |
52-Week Low | $1.09 | $28.90 |
Enterprise Value | $15.81M | $11.89B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
MTCH trades at $38.54, down 0.8% on the day, with a bullish technical signal from moving averages and strong analyst support (17 buy ratings, 0 sell). The company shows solid fundamentals with 4% revenue growth in Q1 2026, an 18.83% net income margin, and positive cash flow trends. Recent news highlights Tinder's turnaround progress and upcoming Q2 2026 earnings announcement on August 4, 2026.
The stock presents upside potential with a consensus price target of $41.63 (8% upside), supported by improving profitability and cash flow generation. Key risks include Tinder's user decline offset by price increases, high debt levels ($3.85B), and competitive pressures in the dating app space. The current valuation at 14.71 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
